A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy

drug protocol number
CRAD001N2301
drug sponsor
Novartis
drug study
Everolimus
drug trial site
KFSH
drug status
Completed
drug phase